



Request under Freedom of Information Act 2000

Request Ref: NGFOI 18/19: 485

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 05/12/18.

I am pleased to be able to provide you with the following information:

Data is provided from the Somerset system for questions 1, 4, 6 for surgery and palliative care.

Can you please clarify what is meant by “any therapy? Meanwhile we have provided figures for surgery and palliative care only.

1. *Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.*

In accordance with the Freedom of Information Act, Exemption section 40 (Personal Information) has been applied. Due to the low numbers involved, 5 or fewer, we have withheld the exact numbers to protect the identities of individuals.

2. *Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;*
disodium pamidronate (Aredia)
ibandronic acid or ibandronate (Bondronat)
sodium clodronate (Bonefos, Clasteon, Loron)
zoledronic acid or zoledronate (Zometa)
denosumab (Xgeva)

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not collate the information you have requested. The pharmacy would record how many doses had been issued but not the indication. All except clodronate are issued as ward stock so indications are not recorded.

3. *Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;*
disodium pamidronate (Aredia)
ibandronic acid or ibandronate (Bondronat)
sodium clodronate (Bonefos, Clasteon, Loron)
zoledronic acid or zoledronate (Zometa)

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not collate the information you have requested. The pharmacy would record how many doses had been issued but not the

indication. All except clodronate are issued as ward stock so indications are not recorded.

4. Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.

39 patients had surgery or palliative care

5. Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

disodium pamidronate (Aredia)

ibandronic acid or ibandronate (Bondronat)

sodium clodronate (Bonafos, Clasteon, Loron)

zoledronic acid or zoledronate (Zometa)

denosumab (Xgeva)

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not collate the information you have requested. The pharmacy would record how many doses had been issued but not the indication. All except clodronate are issued as ward stock so indications are not recorded.

6. Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.

None for surgery or palliative care.

7. Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

disodium pamidronate (Aredia)

ibandronic acid or ibandronate (Bondronat)

sodium clodronate (Bonafos, Clasteon, Loron)

zoledronic acid or zoledronate (Zometa)

denosumab (Xgeva)

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not collate the information you have requested. The pharmacy would record how many doses had been issued but not the indication. All except clodronate are issued as ward stock so indications are not recorded.